Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation
2010

Validation of Gelsolin as a Biomarker

publication Evidence: moderate

Author Information

Author(s): Haverland Nicole, Pottiez Gwënaël, Wiederin Jayme, Ciborowski Pawel

Primary Institution: University of Nebraska Medical Center

Hypothesis

If gelsolin is validated, it may become a candidate as a diagnostic biomarker.

Conclusion

Orthogonal validation using specific antibodies may lead to misleading results in biomarker studies.

Supporting Evidence

  • Immunoreactivity of gelsolin varied greatly between different antibodies.
  • Multiple forms of gelsolin were identified in the samples.
  • Validation methods like Western blot may not accurately reflect the levels of gelsolin.

Takeaway

This study shows that using different antibodies can give different results when testing for gelsolin, which is important for finding reliable disease markers.

Methodology

Samples from human and monkey plasma and CSF were analyzed using Western blot and mass spectrometry.

Potential Biases

Different antibodies may yield inconsistent results, leading to potential bias in biomarker validation.

Limitations

The study faced challenges in validating gelsolin due to variability in antibody performance and the presence of multiple gelsolin forms.

Participant Demographics

Samples were classified based on neurocognitive status without other demographic criteria.

Digital Object Identifier (DOI)

10.1186/1479-5876-8-137

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication